Clinical trials for Anal cancer

87 currently recruiting clinical trials
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06561685
Phase 1a Escalade de dose
Locally Advanced Metastatic Metastatic Castration-resistant Other mutation 1 2 3 or more
Systemic Treatment-Naive
Institut Curie - Paris (Paris)
Eli Lilly et compagnie
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06551142 #2024-513663-10
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif)
GlaxoSmithKline
Phase 1 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06561685
Phase 1b Extension Partie B
Locally Advanced Metastatic Metastatic Castration-resistant Other mutation 1 2 3 or more
Systemic Treatment-Naive
Institut Curie - Paris (Paris)
Eli Lilly et compagnie
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05836324 #2022-502456-31-00
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif)
Incyte Corporation
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05155332 #2020-003902-30
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
Centre Eugene Marquis (Rennes), Hôpital de la Timone AP-HM (Marseille), Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif)
Boehringer Ingelheim
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT07094204 #2025-522082-29-00
Escalade de dose monothérapie
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12C KRAS non G12C Other mutation KRAS G12D 1 2 3 or more
Systemic Treatment-Naive
Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif)
Astellas Pharma Développement mondial, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06297525
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
Gustave Roussy (Villejuif)
Step Pharma, SAS
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04617522 #2022-501508-82-00
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Institut Bergonié (Bordeaux), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Gilead Sciences
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05614739
Cohortes A1 et C1
Locally Advanced Metastatic Metastatic Castration-resistant FGFR 1 2 3 or more
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif)
Eli Lilly et compagnie
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06108479
Cohortes Escalade de dose, cohorte sécurité PK/PD et cohortes basket extension de dose
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
Hôpital de la Timone AP-HM (Marseille), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre Hospitalier​ Universitaire de Bordeaux (Bordeaux), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Institut Bergonié (Bordeaux) (and 4 more...)
Dragonfly Therapeutics